175 related articles for article (PubMed ID: 25424793)
1. Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
Thisyakorn U; Chokephaibulkit K; Kosalaraksa P; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S
Hum Vaccin Immunother; 2014; 10(7):1859-65. PubMed ID: 25424793
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.
Kim DS; Shin SH; Lee HJ; Hong YJ; Lee SY; Choi KM; Oh CE; Kim KH; Juergens C; Patterson S; Giardina PC; Gruber WC; Emini EA; Scott DA
Pediatr Infect Dis J; 2013 Mar; 32(3):266-73. PubMed ID: 23011012
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.
Odusanya OO; Kuyinu YA; Kehinde OA; Shafi F; François N; Yarzabal JP; Dobbelaere K; Rüggeberg JU; Borys D; Schuerman L
Hum Vaccin Immunother; 2014; 10(3):757-66. PubMed ID: 24356787
[TBL] [Abstract][Full Text] [Related]
4. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.
Goldblatt D; Southern J; Andrews NJ; Burbidge P; Partington J; Roalfe L; Valente Pinto M; Thalasselis V; Plested E; Richardson H; Snape MD; Miller E
Lancet Infect Dis; 2018 Feb; 18(2):171-179. PubMed ID: 29174323
[TBL] [Abstract][Full Text] [Related]
8. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.
Dicko A; Santara G; Mahamar A; Sidibe Y; Barry A; Dicko Y; Diallo A; Dolo A; Doumbo O; Shafi F; François N; Strezova A; Borys D; Schuerman L
Hum Vaccin Immunother; 2013 Feb; 9(2):382-8. PubMed ID: 23291945
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
[TBL] [Abstract][Full Text] [Related]
10. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
14. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
[TBL] [Abstract][Full Text] [Related]
15. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine booster in taiwanese toddlers.
Shao PL; Lu CY; Chang LY; Huang FY; Lee CY; Hsueh PR; Huang LM
J Formos Med Assoc; 2006 Jul; 105(7):542-9. PubMed ID: 16877233
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
19. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
[TBL] [Abstract][Full Text] [Related]
20. Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children.
Cho HK; Park IH; Burton RL; Kim KH
J Korean Med Sci; 2016 Jun; 31(6):950-6. PubMed ID: 27247505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
